Literature DB >> 1648341

Acyclovir-resistant varicella zoster responsive to foscarnet.

K J Smith, D C Kahlter, C Davis, W D James, H G Skelton, P Angritt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648341

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


× No keyword cloud information.
  7 in total

Review 1.  "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.

Authors:  A K Field; K K Biron
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

2.  Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus.

Authors:  G Andrei; R Snoeck; D Reymen; C Liesnard; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

3.  Immunoelectron microscopy for rapid diagnosis of varicella-zoster virus in a complicated case of human T-cell lymphotropic virus type 1 infection.

Authors:  E Folkers; J Vreeswijk; F Wagenaar; J G Kapsenberg; H J Hulsebosch; A P Oranje
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

Review 4.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

Review 5.  Recognition and treatment of shingles.

Authors:  A F Nikkels; G E Piérard
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

Review 6.  Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.

Authors:  R Snoeck; G Andrei; E De Clercq
Journal:  Drugs       Date:  1999-02       Impact factor: 11.431

Review 7.  What clinicians need to know about antiviral drugs and viral resistance.

Authors:  R L Hodinka
Journal:  Infect Dis Clin North Am       Date:  1997-12       Impact factor: 5.982

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.